CYP11A1 inhibition as a therapeutic approach for the treatment of castration resistant prostate cancer.

被引：3
|
作者：
Oksala, Riikka
Karimaa, Mari
Simola, Outi
Ramela, Meri
Riikonen, Reetta
Vehmaan-Kreula, Pirjo
Rummakko, Petteri
Wohlfahrt, Gerd
Kallio, Pekka
Mustonen, Mika V. J.
机构：
[1] Orion Corp Orion Pharma, Turku, Finland
[2] Orion Corp Orion Pharma, Espoo, Finland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.340
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
340
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ODM-204, a novel dual inhibitor of CYP17A1 and androgen receptor for the treatment of castration-resistant prostate cancer.
    Kallio, Pekka
    Oksala, Riikka
    Moilanen, Anu
    Riikonen, Reetta
    Rummakko, Petteri
    Malmstrom, Chira
    Mustonen, Mika V. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [22] ODM-208, a novel, small-molecule CYP11A1 inhibitor, demonstrates strong inhibition of steroid biosynthesis and antitumor activity in castration-resistant prostate cancer (CRPC) model.
    Karimaa, Mari
    Kettunen, Henna
    Ramela, Meri
    Mansikka-Savolainen, Suvi
    Chrusciel, Marcin
    Simola, Outi
    Taavitsainen, Paivi
    Wohlfahrt, Gerd
    Rummakko, Petteri
    Vuorela, Annamari
    Fizazi, Karim
    Oksala, Riikka
    CANCER RESEARCH, 2021, 81 (13)
  • [23] Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
    Attard, Gerhardt
    Reid, Alison H. M.
    A'Hern, Roger
    Parker, Christopher
    Oommen, Nikhil Babu
    Folkerd, Elizabeth
    Messiou, Christina
    Molife, L. Rhoda
    Maier, Gal
    Thompson, Emilda
    Olmos, David
    Sinha, Rajesh
    Lee, Gloria
    Dowsett, Mitch
    Kaye, Stan B.
    Dearnaley, David
    Kheoh, Thian
    Molina, Arturo
    de Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) : 3742 - 3748
  • [24] Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab
    Wolff, Johannes M.
    Schmid, Hans-Peter
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2012, 1 (02) : 118 - 119
  • [25] EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
    Heidenreich, Axel
    Bastian, Patrick J.
    Bellmunt, Joaquim
    Bolla, Michel
    Joniau, Steven
    van der Kwast, Theodor
    Mason, Malcolm
    Matveev, Vsevolod
    Wiegel, Thomas
    Zattoni, Filiberto
    Mottet, Nicolas
    EUROPEAN UROLOGY, 2014, 65 (02) : 467 - 479
  • [26] EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
    Mottet, Nicolas
    Bellmunt, Joaquim
    Bolla, Michel
    Joniau, Steven
    Mason, Malcolm
    Matveev, Vsevolod
    Schmid, Hans-Peter
    Van der Kwast, Theo
    Wiegel, Thomas
    Zattoni, Filiberto
    Heidenreich, Axel
    EUROPEAN UROLOGY, 2011, 59 (04) : 572 - 583
  • [27] MCT inhibition as a therapeutic strategy to target Enzalutamide-resistant prostate cancer.
    Bhattacharjee, Sayani
    Doan, Jonathan
    Wynn, Rebecca
    Nadiminty, Nagalakshmi
    CANCER RESEARCH, 2021, 81 (13)
  • [28] EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
    Mottet, N.
    Bellmunt, J.
    Bolla, M.
    Joniau, S.
    Mason, M.
    Matveev, V.
    Schmid, H. P.
    van der Kwast, T.
    Wiegel, T.
    Zattoni, F.
    Heidenreich, A.
    ACTAS UROLOGICAS ESPANOLAS, 2011, 35 (10): : 565 - 579
  • [29] SPOP mutation as a predictive marker for treatment of metastatic castration-resistant prostate cancer.
    Stangl, Andrew
    Willner, Christopher
    Maahs, Lucas
    Burmeister, Charlotte
    Hwang, Clara
    Pilling, Amanda
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [30] PARP inhibition in castration-resistant prostate cancer
    Nappi, Lucia
    Gleave, Martin E.
    FUTURE ONCOLOGY, 2016, 12 (05) : 577 - 580
12345